Clinical trial · Observational
Early Gastric Cancer in the Spanish EURECCA Registry
Differences Between Clinical and Pathological Staging in Early Gastric Cancer (EGC): Evaluation of the Potential Impact of Applying Standard and Expanded Asian Endoscopic Resection Criteria in a Western Cohort and Analysis of Disease Progression and Long-Term Survival
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early gastric cancer (EGC) is increasingly diagnosed in Western countries; however, important differences remain with Eastern populations regarding staging accuracy, treatment strategies, and the risk of lymph node metastasis. While endoscopic resection is the standard treatment for selected EGC in Asia based on well-established criteria, the applicability of these criteria to Western populations remains uncertain because of differences in epidemiology, clinical practice, and pathological characteristics. This multicenter retrospective cohort study, based on the Spanish EURECCA Registry, aims to evaluate the concordance between clinical and pathological staging, determine the real incidence and predictors of lymph node metastasis in patients with pathological T1 gastric cancer, assess the applicability of standard and expanded Asian endoscopic resection criteria in a Western cohort, and analyze long-term oncological outcomes, including recurrence and overall survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Gastric Cancer | Early Gastric Carcinoma | ALIAS | 0.90 |
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Early Gastric Cancer Cohort
- description
- Patients with surgically treated early gastric adenocarcinoma (pathological T1) included in the multicenter Spanish EURECCA Registry between January 2014 and December 2022. Patients underwent curative-intent gastrectomy with lymph node dissection according to routine clinical practice at participating centers. Clinical, pathological, treatment, and follow-up data were retrospectively analyzed.
Primary outcomes (2)
- measure
- Percentage of Participants With Concordant Clinical and Pathological Staging
- timeFrame
- Baseline
- description
- Percentage of participants in whom preoperative clinical staging (cT and cN) was concordant with final pathological staging (pT and pN). Concordance will be assessed by comparing clinical and pathological tumor depth and lymph node status.
- measure
- Lymph node metastasis
- timeFrame
- Baseline
- description
- Percentage of participants with pathological lymph node metastasis (pN+) among patients with pathological T1 gastric adenocarcinoma. Lymph node status will be determined from the definitive pathological examination of the surgical specimen.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (≥18 years of age) * Clinical diagnosis of early gastric cancer (cT1) before surgery. * Curative-intent gastrectomy with lymph node dissection performed between * January 2014 and December 2022. * Histologically confirmed gastric adenocarcinoma. * Inclusion in the multicenter Spanish EURECCA Registry. * Availability of complete preoperative clinical staging, pathological findings, and follow-up data required for the study analyses. Exclusion Criteria: * Receipt of neoadjuvant therapy before surgery. * Incomplete pathological data precluding accurate tumor staging or lymph node assessment. * Non-adenocarcinoma gastric tumors.
References
Publications (0)
Data not yet available